AM-1476 is under clinical development by AnaMar and currently in Phase I for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase I drugs for Systemic Sclerosis (Scleroderma) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AM-1476’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AM-1476 is under development for the treatment of idiopathic pulmonary fibrosis (IPF), interstitial lung disease, systemic sclerosis, liver fibrosis, cardiac fibrosis, fibrotic tumors and graft-versus-host disease. The therapeutic candidate is administered through oral route. It acts by targeting 5-hydroxytryptamine receptor 2B (5-HT-2B).
AnaMar, a subsidiary of Koncentra Holding AB, is a drug discovery company that discovers, develops and commercializes therapeutic strategies to treat debilitating inflammation, fibrosis and pain. It develops drug candidates from several chemical classes on the receptors and shows potent anti-inflammatory and pain relieving effects. It carries out research to discover, validate, screen and optimize new disease-modifying drugs to target novel cellular pathways and suppress inflammation, pain and fibrosis. AnaMar’s pipeline projects comprise AMAP102, AM1030-cream, Mitra and Sting. The company develops 5-HT2B receptor antagonists with potential use in a wide range of human diseases. AnaMar is headquartered in Lund, Sweden.
For a complete picture of AM-1476’s drug-specific PTSR and LoA scores, buy the report here.